Abstract
Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Current Alzheimer Research
Title: Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Volume: 5 Issue: 5
Author(s): James G. McLarnon and Jae K. Ryu
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Abstract: Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Export Options
About this article
Cite this article as:
McLarnon G. James and Ryu K. Jae, Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908874
DOI https://dx.doi.org/10.2174/156720508785908874 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Myths and Facts Concerning the Use of Statins in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design Studies on the Effect of the Apolipoprotein E Genotype on the Lipid Profile in Alzheimers Disease
Current Alzheimer Research Galanin/GALP Receptors and CNS Homeostatic Processes
CNS & Neurological Disorders - Drug Targets Onset Age and Clinical Heterogeneity of Dementias: A Diagnostic and Therapeutic Approach
Current Psychopharmacology From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Editorial: Advances in Understanding Alzheimer's Disease, and the Contributions of Current Alzheimer Research: Ten Years on and Beyond
Current Alzheimer Research Influence of Impaired Liver Methionine Metabolism on the Development of Vascular Disease and Inflammation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews A MicroRNA-BDNF Negative Feedback Signaling Loop in Brain: Implications for Alzheimer’s Disease
MicroRNA Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design